P01.06 Overcoming resistance to ICI therapy by downregulating the expression of neuropilin-1 with antisense oligonucleotides

• A Zippelius,
• L Rodríguez,
• J Festag,
• S Michel,
• R Klar,
• F Jaschinski,
• A Maaske,
• N Kirchhammer,
• M Buchi

Affiliations

A Zippelius

2Cancer Immunology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland

L Rodríguez

Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain

J Festag

1Secarna Pharmaceuticals GmbH and Co. KG, Planegg, Germany

S Michel

Secarna Pharmaceuticals GmH and Co. KG, Planegg/Martinsried, Germany

R Klar

Secarna Pharmaceuticals GmH and Co. KG, Planegg/Martinsried, Germany

F Jaschinski

Secarna Pharmaceuticals GmH and Co. KG, Planegg/Martinsried, Germany

A Maaske

1Secarna Pharmaceuticals GmbH and Co. KG, Planegg, Germany

N Kirchhammer

2Cancer Immunology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland

M Buchi

2Cancer Immunology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland